Regulatory Bayer plans filings for cardiac amyloidosis imaging agent PharmaphorumArmed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis.CardiovascularRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) Pharmaphorum Armed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis. Cardiovascular Read full story Post navigation Previous: Roche buys AI-powered diagnostics player PathAINext: Angelini inks $4.1B Catalyst buy to enter US rare disease market Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026